Levonorgestrel Butanoate for Female Contraception

Pharmacokinetic/Pharmacodynamic Evaluation of Levonorgestrel Butanoate for Female Contraception (LB PK-PD) – RECRUITING

This is a multi-center, open-label study that aims to determine the appropriate dosage of the injectable formulation of levonorgestrel butanoate (LB) for female contraception.

Initially, participants will undergo a screening period to confirm healthy ovulatory function. Thereafter, participants will receive a single injection of LB. Participants will frequently attend our OB/GYN clinic at BMC for serum samples, transvaginal ultrasound, and cervical mucus evaluation. Participants will be followed until their menses resume, which typically occurs 12-26 weeks after injection.

Healthy women ages 18-44, who are not at risk for pregnancy and who do not use hormonal contraception (heterosexually abstinent, heterosexually active with previous tubal sterilization, heterosexually active with a vasectomized monogamous partner, heterosexually active and use male or female condoms) may qualify.

Want more information about this study? Call the BEACON Research Team at 617-383-3500 or email us at dg-infofp@bmc.org.

You may also securely fill out a pre-screening questionnaire online by following the link: https://redcap.bumc.bu.edu/surveys/?s=EPD9JA93J9


OB/GYN Clinic, Yawkey Ambulatory Care Center, 5th Floor, Boston Medical Center, 850 Harrison Avenue, Boston, MA 02118
dg-infofp@bmc.org | 617-383-3500